pat-sm6 receives orphan drug designationfor mm, page-30

At any point in time, there's going to be a finite cash supply for spec stocks in general let alone the biotech sector and rightly or wrongly, this end of the market currently appears somewhat unbalanced regarding the distribution of this available cash. Perhaps PAB need to sell their story a little better to pull a percentage of that capital into their yard. It's not difficult to see some massive losses for the inexperienced when some of these absurd runs come to their inevitable ends. Looking at the Pattos preso for ISN......Providing all goes perfectly to plan, they are currently trading at a forward (2 years) P/E ratio of around 74 to 1. The market's gone absolutely nuts.

I suspect that once these heavily overbought bios begin printing lower highs, the deck of cards will collapse and it's logical to expect a decent percentage of this cash to look for a new home within the sector. If the above pans out, i'll jump onboard because i can't see PAB going unnoticed forever.

The fundamentals here suggest that your day will come!